Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 51

Results For "FY"

2474 News Found

Dr. Reddy's Laboratories Q1 FY2024 consolidated PAT jumps to Rs. 1402.5 Cr
News | July 28, 2023

Dr. Reddy's Laboratories Q1 FY2024 consolidated PAT jumps to Rs. 1402.5 Cr

The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023


Astec LifeSciences posts consolidated Q1FY24 loss at Rs. 8.19 Cr
News | July 28, 2023

Astec LifeSciences posts consolidated Q1FY24 loss at Rs. 8.19 Cr

Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023


Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr
News | July 28, 2023

Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr

The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023


Dr. Lal Path Labs Q1FY24 consolidated PAT up at Rs. 82.6 Cr
News | July 28, 2023

Dr. Lal Path Labs Q1FY24 consolidated PAT up at Rs. 82.6 Cr

Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023


Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr
News | July 28, 2023

Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr

The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023


Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr
News | July 27, 2023

Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr

Cipla has reported total income of Rs. 6465.18 crores during the period ended June 30, 2023


Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
News | July 26, 2023

Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr

Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24


Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr
News | July 26, 2023

Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr

Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023


Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
News | July 22, 2023

Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24

The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.


Dabur India expects 10%+ consolidated growth in Q1 FY24
News | July 07, 2023

Dabur India expects 10%+ consolidated growth in Q1 FY24

However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.